Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antibody Persistence against Diphtheria, Tetanus, Pertussis, Hepatitis B, Measles, Mumps and Rubella in Thai Children Following Immunization with Pentavalent and Hexavalent Vaccines
TCTR20260626009Not yet recruiting
- Sponsor
- Ratchadaphiseksomphot Endowment Fund
- Start
- Jul 2026
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Trial of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated), tetanus toxoid, pertussis vaccine, Hepatitis B vaccine, measles virus vaccine live and 2 more in diphtheria, Tetanus, pertussis and 4 more, sponsored by Ratchadaphiseksomphot Endowment Fund. Primary endpoint: Seroprotection rates for each antigen. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)tetanus toxoidpertussis vaccineHepatitis B vaccinemeasles virus vaccine live
03
Conditions
diphtheriaTetanuspertussishepatitis B (HBV)measles
Beyond the preview
Go deeper on TCTR20260626009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20260626009.